Protective Role of Naringenin Against Doxorubicin-Induced Cardiotoxicity in a Rat Model: Histopathology and mRNA Expression Profile Studies

Male Wistar rats in a doxorubicin-induced cardiotoxicity model

Naringenin 50 mg/kg/day orally for 10 consecutive weeks

Doxorubicin 3 mg/kg intravenously for 10 consecutive weeks without naringenin

Biochemical alterations (LDH, troponin T, MDA), cardiac enzymatic activities (SOD, GPx, CAT), histopathological observations, and mRNA expression levels of inflammatory markers (TGF-β1, TNF-α, IL-6, IL-10)surrogate